Percutaneous Cholecystostomy is a Feasible and Safe Option for High-Risk Acute Cholecystitis Patients

IF 0.3 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Clinical and Experimental Health Sciences Pub Date : 2023-10-04 DOI:10.33808/clinexphealthsci.1347081
Ömer AYDINER, Hüseyin Kemal RAŞA
{"title":"Percutaneous Cholecystostomy is a Feasible and Safe Option for High-Risk Acute Cholecystitis Patients","authors":"Ömer AYDINER, Hüseyin Kemal RAŞA","doi":"10.33808/clinexphealthsci.1347081","DOIUrl":null,"url":null,"abstract":"Objective: The best option for treating high-risk patients with acute cholecystitis is still being determined. We evaluated our high-risk acute cholecystitis patients in whom we preferred percutaneous cholecystostomy and aimed to determine whether this approach was safe and feasible. 
 Methods: We retrospectively reviewed our 71 patients in whom we performed percutaneous cholecystostomy between May 2019 and July 2023. All procedures were performed with local anaesthesia under ultrasonographic guidance via the transhepatic route. The catheters were removed when the signs of acute cholecystitis were significantly regressed or when the catheters were found to be ineffective. The catheters of those eligible for surgery were removed during the operations. 
 Results: All procedures were successful without failure, and no significant complications developed in the post-intervention period. Pain at the catheter insertion site (20 patients) was the leading minor complication, and in one patient, bilioma was detected and percutaneously drained. The procedure was ineffective in 7 patients (9.85%), and the catheters were removed. In 22 patients (31%), interval cholecystectomy surgery was performed. In the subgroup of patients whose catheters were adequate and were not operated (5 patients), the catheters were removed after an average of 27.2 days. The mean length of stay was 9.6 days, and four patients died (5.6%) during the index hospitalization. 
 Conclusion: Our findings suggest that percutaneous cholecystostomy is a feasible, safe and highly effective treatment option for acute cholecystitis in high-risk patients.","PeriodicalId":10192,"journal":{"name":"Clinical and Experimental Health Sciences","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33808/clinexphealthsci.1347081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The best option for treating high-risk patients with acute cholecystitis is still being determined. We evaluated our high-risk acute cholecystitis patients in whom we preferred percutaneous cholecystostomy and aimed to determine whether this approach was safe and feasible. Methods: We retrospectively reviewed our 71 patients in whom we performed percutaneous cholecystostomy between May 2019 and July 2023. All procedures were performed with local anaesthesia under ultrasonographic guidance via the transhepatic route. The catheters were removed when the signs of acute cholecystitis were significantly regressed or when the catheters were found to be ineffective. The catheters of those eligible for surgery were removed during the operations. Results: All procedures were successful without failure, and no significant complications developed in the post-intervention period. Pain at the catheter insertion site (20 patients) was the leading minor complication, and in one patient, bilioma was detected and percutaneously drained. The procedure was ineffective in 7 patients (9.85%), and the catheters were removed. In 22 patients (31%), interval cholecystectomy surgery was performed. In the subgroup of patients whose catheters were adequate and were not operated (5 patients), the catheters were removed after an average of 27.2 days. The mean length of stay was 9.6 days, and four patients died (5.6%) during the index hospitalization. Conclusion: Our findings suggest that percutaneous cholecystostomy is a feasible, safe and highly effective treatment option for acute cholecystitis in high-risk patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
经皮胆囊造瘘术是治疗高危急性胆囊炎的一种安全可行的方法
目的:高危急性胆囊炎患者的最佳治疗方案仍有待确定。我们评估了高危急性胆囊炎患者,我们选择经皮胆囊造口术,目的是确定这种方法是否安全可行。& # x0D;方法:我们回顾性分析了2019年5月至2023年7月间接受经皮胆囊造瘘术的71例患者。所有手术均在超声引导下经肝行局部麻醉。当急性胆囊炎症状明显消退或发现导管无效时,拔除导管。符合手术条件的患者在手术过程中取出导管。& # x0D;结果:所有手术均成功,无失败,术后无明显并发症发生。导管插入部位疼痛(20例)是主要的轻微并发症,其中1例患者发现胆囊瘤并经皮引流。7例患者(9.85%)手术无效,导管被拔除。22例(31%)患者行间隔胆囊切除术。在置管充足且未手术的患者亚组(5例)中,平均27.2天后取出置管。平均住院时间9.6 d,指数住院期间死亡4例(5.6%)。& # x0D;结论:经皮胆囊造瘘术是治疗高危患者急性胆囊炎的一种可行、安全、高效的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical and Experimental Health Sciences
Clinical and Experimental Health Sciences MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
0.00%
发文量
73
期刊最新文献
Presumptive Molecular Interconnections Between COVID-19 And Huntington’s Disease Enhanced Enzyme Inhibitory Effects of the Nanohybrid Eggplant Extract: An Unusual Pharmaceutical Form for Medicinal Plant The Validity and Reliability of the Postpartum Symptom Inventory in Turkish Women The Effect of Sex Education and Counseling Based on the Ex-PLISSIT Model on Sexual Life in Primigravidas Ketogenic Diet Interventions in Inborn Errors of Metabolism: A Review Article
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1